A Single-center, Open Label, Randomized Cross-over Study to Compare 3 Modified-release Formulations With Different Release Profiles of RO4917523 Along With a Reference Intravenous Microdose Infusion
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2015
Price : $35 *
At a glance
- Drugs Basimglurant (Primary)
- Indications Fragile X syndrome; Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Roche
- 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 18 Jun 2013 Actual initiation date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.